Table 2.

Prevalence of low-volume metastases in low-, intermediate- or high-risk subgroups.

First Author	Study Period	Definition of Risk	Country	Number of Patients	Patients with LVM (%)	Patients with MM (%)	Patients with ITCs (%)
Raimond [73]	2000–2012	Apparent stage I, ESMO low- § and intermediate-risk ¥ EC	France	136	15 (11)	NR	NR
Todo [74]	1997–2004	Intermediate-risk EC: early-stage with any of the following: >50% MI, grade 3 disease, non-endometrioid, with cervical involvement, LVSI, PPC	Japan	61	9 (14.8)	3 (5)	6 (9.8)
Zahl-Eriksson [75]	2004–2013	Low-risk EC: MI < 50%, endometrioid, any grade	USA	642	22 (3.4)	2 (0.3)	20 (3.1)
Ducie [76]	2004–2013	Intermediate-risk EC: apparent early-stage with >50% MI, any grade, endometrioid; high-risk EC: serous, clear-cell	USA	202	20 (9.9)	8 (4)	12 (5.9)
Persson [33]	2014-2018	High-risk EC: apparent early stage with any of the following: endometrioid grade 3, non-endometrioid, >50% MI, CSI, non-diploid cytometry	Sweden	257	19 (7.4)	9 (3.5)	10 (3.9)
Bjornholt [77]	2017–2022	Apparent early-stage endometrioid EC, low-grade, any MI	Denmark	591	36 (5.7)	20 (3.1)	16 (2.6)
Burg [78]	2016–2021	Apparent early-stage, ESGO low- £ and intermediate-risk ¤ EC	Netherlands	152	NR	NR	3 (2)

Abbreviations: EC: endometrial carcinoma; LVM: low-volume metastases; MM: micro-metastases; ITCs: isolated tumor cells; LVSI: lymphovascular space invasion; PPC: positive peritoneal cytology; MI: myometrial invasion; NR: not reported. ^§ ESMO low-risk: endometrioid, grade 1–2, stage IA; ^¥ ESMO Intermediate-risk: endometrioid, stage IA, grade 3, or stage IB grade 1 or 2; ^£ ESGO low-risk: stage IA endometrioid, low-grade, LVSI negative or focal; ^¤ ESGO intermediate-risk: stage IB endometrioid, low-grade, LVSI negative or focal OR stage IA endometrioid, high-grade, LVSI negative or focal OR stage IA non-endometrioid (serous, clear cell, undifferentiated carcinoma, carcinosarcoma, mixed) without myometrial invasion.